Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Theravance Biopharma (NASDAQ:TBPH) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16), Zacks reports. Theravance Biopharma had a negative return on equity of 24.23% and a negative net margin of 78.18%. The company had revenue of $16.87 million for the quarter, compared to the consensus estimate of $16.11 million. During the same quarter in the previous year, the company posted ($0.17) EPS.

Theravance Biopharma Stock Performance

NASDAQ:TBPH traded up $0.98 during mid-day trading on Wednesday, hitting $9.89. 187,885 shares of the stock were exchanged, compared to its average volume of 345,884. The stock has a market capitalization of $483.84 million, a price-to-earnings ratio of -9.92 and a beta of 0.25. The firm’s 50-day simple moving average is $8.32 and its 200 day simple moving average is $8.68. Theravance Biopharma has a fifty-two week low of $7.44 and a fifty-two week high of $11.71.

Analyst Ratings Changes

Several research firms recently issued reports on TBPH. Leerink Partnrs lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. StockNews.com lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. TD Cowen dropped their price objective on Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Leerink Partners lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. Finally, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $13.75.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.